PCSK9 In The Spotlight Ahead Of AHA Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Publication of full Phase II results for Sanofi/Regeneron’s SRA236553 in the New England Journal of Medicine put the focus on the PCSK9 class days ahead of the annual AHA meeting, where Amgen and Pfizer will be presenting new data for rival drugs.